156.29
price down icon0.69%   -1.08
 
loading
Schlusskurs vom Vortag:
$157.37
Offen:
$157.32
24-Stunden-Volumen:
1.69M
Relative Volume:
0.30
Marktkapitalisierung:
$193.79B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
21.27
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+3.39%
1M Leistung:
+5.83%
6M Leistung:
+12.80%
1J Leistung:
+32.62%
1-Tages-Spanne:
Value
$155.80
$157.57
1-Wochen-Bereich:
Value
$147.26
$160.51
52-Wochen-Spanne:
Value
$114.02
$160.51

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
17,000
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2026-10-29
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, MRK, NVS

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
GILD icon
GILD
Gilead Sciences Inc
156.29 193.79B 29.79B 9.22B 10.23B 7.3494
LLY icon
LLY
Lilly Eli Co
1,265.94 1.13T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
257.07 619.52B 97.93B 21.04B 17.80B 8.6278
ABBV icon
ABBV
Abbvie Inc
284.59 502.90B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
146.99 362.64B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
151.47 287.90B 54.66B 13.58B 16.05B 7.0171

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-07-21 Herabstufung Leerink Partners Outperform → Market Perform
2026-07-06 Hochstufung HSBC Securities Hold → Buy
2026-05-20 Hochstufung Maxim Group Hold → Buy
2026-03-10 Eingeleitet Jefferies Buy
2026-02-20 Eingeleitet Barclays Equal Weight
2026-02-11 Bestätigt Needham Buy
2026-01-07 Fortgesetzt UBS Buy
2025-11-24 Fortgesetzt Truist Buy
2025-11-13 Eingeleitet Scotiabank Sector Outperform
2025-08-19 Hochstufung Daiwa Securities Neutral → Outperform
2025-08-08 Hochstufung Truist Hold → Buy
2025-07-25 Hochstufung Needham Hold → Buy
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-03-04 Bestätigt Oppenheimer Outperform
2025-02-18 Hochstufung Deutsche Bank Hold → Buy
2025-02-13 Hochstufung DZ Bank Hold → Buy
2025-01-10 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Buy
2024-11-08 Herabstufung Maxim Group Buy → Hold
2024-10-21 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-10-07 Hochstufung Wells Fargo Equal Weight → Overweight
2024-07-08 Hochstufung Raymond James Mkt Perform → Outperform
2024-05-01 Bestätigt Maxim Group Buy
2024-04-24 Hochstufung HSBC Securities Reduce → Hold
2024-02-22 Herabstufung Truist Buy → Hold
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
04:05 AM

Gilead Sciences, Inc. $GILD Shares Sold by Curated Wealth Partners LLC - MarketBeat

04:05 AM
pulisher
03:52 AM

Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation? - Kalkine Media

03:52 AM
pulisher
03:07 AM

Gilead Sciences, Inc. $GILD Stock Sold by Assenagon Asset Management S.A. - MarketBeat

03:07 AM
pulisher
12:25 PM

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace

12:25 PM
pulisher
Oct 15, 2026

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Yahoo Finance

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences (GILD) Rises Higher Than Market: Key Facts - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - Business Wire

Oct 15, 2026
pulisher
Oct 15, 2026

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences Inc Stock (GILD) Moved Up by 3.67% on Oct 15: Key Drivers Unveiled - TradingKey

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences (NASDAQ:GILD) Hits New 52-Week HighHere's What Happened - MarketBeat

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences stock hits all-time high at 157.32 USD - Investing.com

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Oct 15, 2026
pulisher
Oct 14, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 14, 2026
pulisher
Oct 14, 2026

What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership? - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers - BioSpace

Oct 14, 2026
pulisher
Oct 14, 2026

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal - Reuters

Oct 14, 2026
pulisher
Oct 14, 2026

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Business Wire

Oct 14, 2026
pulisher
Oct 13, 2026

Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 13, 2026
pulisher
Oct 13, 2026

Earnings Preview: What to Expect From Gilead Sciences’ Report - Barchart.com

Oct 13, 2026
pulisher
Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 12, 2026

Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Can Gilead (GILD) Stock Continue Rising in 2027? - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 12, 2026

BofA raises Gilead Sciences stock price target on growth outlook By Investing.com - Investing.com India

Oct 12, 2026
pulisher
Oct 12, 2026

RBC raised target for Gilead Sciences stock to USD 126.00 - ad-hoc-news.de

Oct 12, 2026
pulisher
Oct 11, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool

Oct 11, 2026
pulisher
Oct 11, 2026

Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? - Yahoo Finance

Oct 11, 2026
pulisher
Oct 11, 2026

Is Gilead Sciences (GILD) Undervalued After Strong Q2 Sales? - Yahoo Finance

Oct 11, 2026
pulisher
Oct 09, 2026

Gilead Sciences (GILD) Laps the Stock Market: Here's Why - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 09, 2026
pulisher
Oct 09, 2026

RBC raises target for Gilead Sciences stock to USD 126.00 - AD HOC NEWS

Oct 09, 2026
pulisher
Oct 09, 2026

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo! Finance Canada

Oct 08, 2026
pulisher
Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat

Oct 08, 2026
pulisher
Oct 08, 2026

Cantor Fitzgerald Reaffirms Overweight Rating for Gilead Sciences (NASDAQ:GILD) - MarketBeat

Oct 08, 2026
pulisher
Oct 07, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) - TradingView

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co. - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

U.S. Stocks Slip Ahead of Fed Minutes; Gilead Sciences (GILD) Ga - GuruFocus

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences (NASDAQ:GILD) Stock Price Target Cut by Morgan Stanley - MarketBeat

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences Is Maintained at Overweight by Morgan Stanley - Moomoo

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences stock gains 2.57 percent after AI agreement expands - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 07, 2026

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) - Benzinga

Oct 07, 2026
pulisher
Oct 07, 2026

JPMorgan Adjusts Price Target on Gilead Sciences to $170 From $160 - marketscreener.com

Oct 07, 2026
pulisher
Oct 07, 2026

Gilead Sciences signs five-year DevOps agreement with Cognizant - Pharmaceutical Technology

Oct 07, 2026

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Gilead Sciences Inc-Aktie (GILD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
ANDREW DICKINSON
Officer
Oct 15 '26
Proposed Sale
156.22
3,000
468,660
0
O'Day Daniel Patrick
Chairman & CEO
Oct 01 '26
Sale
147.90
15,000
2,218,508
566,683
JOHANNA MERCIER
Officer
Sep 15 '26
Proposed Sale
144.22
3,000
432,646
0
Dickinson Andrew D
Chief Financial Officer
Sep 15 '26
Sale
145.29
3,000
435,870
164,096
Mercier Johanna
Chief Comm & Corp Aff Officer
Sep 15 '26
Sale
144.22
3,000
432,646
116,684
ANDREW DICKINSON
Officer
Sep 15 '26
Proposed Sale
145.29
3,000
435,870
0
O'Day Daniel Patrick
Chairman & CEO
Sep 01 '26
Sale
148.64
15,000
2,229,592
577,133
WELTERS ANTHONY
Director
Aug 26 '26
Option Exercise
61.06
18,000
1,099,052
23,176
ANTHONY WELTERS
Director
Aug 26 '26
Proposed Sale
148.77
18,000
2,677,860
0
WELTERS ANTHONY
Director
Aug 26 '26
Sale
148.62
18,000
2,675,220
12,894
NVO NVO
$39.23
price up icon 0.04%
PFE PFE
$29.59
price up icon 0.53%
$436.04
price up icon 0.46%
AZN AZN
$165.75
price down icon 0.56%
BMY BMY
$60.80
price up icon 0.37%
NVS NVS
$151.47
price up icon 0.72%
Kapitalisierung:     |  Volumen (24h):